Evidence map›Paper›PMID 26104473›Full record

ArticleSchizophrenia research2015

Abnormal N-acetylglucosaminyltransferase expression in prefrontal cortex in schizophrenia.

Jordyn M Kippe, Toni M Mueller, Vahram Haroutunian, James H Meador-Woodruff

Abstract read
In one paragraph

Article in Schizophrenia research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Downregulated AKT-mTOR signaling pathway proteins in dorsolateral prefrontal cortex in Schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jordyn M KippeDepartment of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL USA. Electronic address: kippe1jm@uab.edu.
Toni M MuellerDepartment of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL USA.
Vahram HaroutunianDepartment of Psychiatry, Mount Sinai School of Medicine, New York, NY USA.
James H Meador-WoodruffDepartment of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL USA.
University of Alabama at Birmingham · USIcahn School of Medicine at Mount Sinai · US

Funding

White Matter Abnormalities in SchizophreniaP50MH066392 · NIMH · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI BUXBAUM, JOSEPH D. · 2002 to 2012
$18.6M
Subcellular Glutamate Receptor Defects in SchizophreniaR01MH053327 · NIMH · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MEADOR-WOODRUFF, JAMES H · 1995 to 2015
$5.8M
Cortico-thalamic Glutamate/GABA mRNA in schizophreniaR01MH064673 · NIMH · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI HAROUTUNIAN, VAHRAM · 2003 to 2012
$3.4M
NIMH NIH HHS MH064673NIMH NIH HHS MH066392NIMH NIH HHS MH53327NIMH NIH HHS P50 MH066392NIMH NIH HHS R01 MH053327NIMH NIH HHS R01 MH064673
6 · The paper itself

Abstract

Changes in the extent of the posttranslational modification glycosylation have been previously reported in several brain regions in schizophrenia. Quality control within the endoplasmic reticulum and Golgi, branching of glycans, intracellular trafficking and targeting, protein-protein interactions, and endocytosis are processes regulated by both N-linked and O-linked glycosylation. Previous studies in schizophrenia have found altered glycan biosynthesis and abnormal glycan levels in cerebrospinal fluid (CSF) and plasma, as well as altered expression in frontal cortex of glycosyltransferase transcripts encoding proteins associated with both N- and O-linked glycosylation. The N-acetylglucosaminyltransferases (GlcNAcTs) are glycosylating enzymes that play a key role in adding N-acetylglucosamine (GlcNAc) to substrates to facilitate their proper trafficking, intracellular targeting, and cellular function. Given previous results indicating abnormal glycosylation in schizophrenia, we hypothesized that these GlcNAcTs may be abnormally expressed in this illness. We measured protein expression of nine distinct GlcNAcTs by Western blot analysis in postmortem samples of dorsolateral prefrontal cortex (DLPFC) from twelve pairs of elderly patients with schizophrenia and comparison subjects. We found decreased protein expression of UDP-GlcNAc:BetaGal Beta-1,3 GlcNAcT 8 (B3GNT8) and mannosyl (alpha-1,3-)-glycoprotein beta-1,4 GlcNAcT (MGAT4A) expression in schizophrenia. These data provide further evidence that glycosylation is dysregulated in schizophrenia, and suggest a potential mechanism associated with alterations in protein function, trafficking, and intracellular targeting in this illness.

Indexed as

AgedAnimalsAntipsychotic AgentsBlotting, WesternFemaleGray MatterHaloperidolHumansMaleN-AcetylglucosaminyltransferasesPrefrontal CortexRats, Sprague-DawleySchizophreniaAntipsychotic AgentsHaloperidolhaloperidol decanoateN-AcetylglucosaminyltransferasesB3GNT8MGAT4AN-glycosylationO-glycosylationPostmortem brainPosttranslational modifications

Identifiers

PMID26104473
PMCPMC4512847
OpenAlexW2145495351

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.